The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors

D. N. Rose, C. B. Schechter and A. L. Silver

Isoniazid chemoprophylaxis recommendations include its use in persons who have positive tuberculin reactions, but neither recent conversion nor other activation risk factors, only if they are under age 35 years. Above this threshold, the isoniazid hepatitis risk is said to outweigh the benefit of preventing activation. Because this policy is controversial, we performed a decision analysis contrasting those who take with those who decline isoniazid therapy according to three outcome measures: life expectancy, likelihood of illness (isoniazid hepatitis and active tuberculosis), and likelihood of fatal illness. We found no threshold between ages 10 and 80 years by the measures of life expectancy and likelihood of fatal illness; isoniazid benefits outweigh risks for all, though the margin is small for the elderly. A threshold exists only in the likelihood of illness: isoniazid risks outweigh benefits for those aged 50 to 65 years. Only extreme variations of assumptions affect these findings. Chemoprophylaxis recommendations should include low-risk tuberculin reactors over age 35 years.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tuberculosis Among Foreign-Born Persons in the United States
Cain et al.
JAMA 2008;300:405-412.
ABSTRACT | FULL TEXT  

Incidence of Tuberculosis among a Cohort of Tuberculin-Positive Refugees in Australia . Reappraising the Estimates of Risk
MARKS et al.
Am. J. Respir. Crit. Care Med. 2000;162:1851-1854.
ABSTRACT | FULL TEXT  

Benefits of Screening for Latent Mycobacterium tuberculosis Infection
Rose
Arch Intern Med 2000;160:1513-1521.
ABSTRACT | FULL TEXT  

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection . This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999.
Am. J. Respir. Crit. Care Med. 2000;161:S221-247.
FULL TEXT  

Tuberculosis: 10. Prevention
Menzies et al.
CMAJ 1999;161:717-724.
FULL TEXT  

Hepatotoxicity Associated With Isoniazid Preventive Therapy: A 7-Year Survey From a Public Health Tuberculosis Clinic
Nolan et al.
JAMA 1999;281:1014-1018.
ABSTRACT | FULL TEXT  

Tuberculosis among Health Care Workers
Menzies et al.
NEJM 1995;332:92-98.
FULL TEXT  

Isoniazid Prophylaxis: The Importance of Individual Values
Dolan and Bordley
Med Decis Making 1994;14:1-8.
ABSTRACT